Cargando…
Anticoagulation Management and Outcomes in Covid-19 Patients:a Multi-Center Retrospective Cohort Study
Introduction Coronavirus disease (COVID-19) may induce a hypercoagulable state, leading to microvascular and macrovascular thromboses, as shown in observational and autopsy studies (Giannis, Ziogas, and Gianni 2020; Carsana et al. 2020; Lax et al. 2020). Empiric therapeutic anticoagulation has been...
Autores principales: | Kaur, Jasmeet, Sule, Anupam A, Koehler, Tracy, Krishnamoorthy, Geetha, DeLongpre, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330299/ http://dx.doi.org/10.1182/blood-2020-140997 |
Ejemplares similares
-
Optimal Anticoagulant Dosing in Patients with COVID-19, a Retrospective Review
por: Carrillo, Alessandra, et al.
Publicado: (2021) -
Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
por: Goshua, George, et al.
Publicado: (2020) -
The Impact of Different Prophylactic Anticoagulation Doses on the Outcomes of Patients with COVID-19
por: Jiménez-Soto, Rodolfo, et al.
Publicado: (2020) -
Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients
por: Ashraf, Farah, et al.
Publicado: (2020) -
Increasing Doses of Anticoagulation Are Associated with Improved Survival in Hospitalized COVID-19 Patients
por: Ionescu, Filip, et al.
Publicado: (2020)